Ken received his Ph.D. from the University of Utah in 1996 and came to Eli Lilly and Co. in 1998 from the Memorial Sloan Kettering Cancer Research Center as a senior organic chemist. He worked on several projects as a medicinal chemist in the areas of anxiety, depression and inflammatory disorders, and he has been involved in many cross-functional Lilly research collaborations. In 2008, Ken took on new a new role as a Head in Drug Disposition with responsibilities across the in-vitro, transporter, in-silico, Lead Generation and the isotopic chemistry groups within Drug Disposition. In 2009, Ken moved to Global External R&D (GER&D) where he worked to better define the approach to sourcing and performing diligence assessments of pre-clinical and discovery level opportunities. Ken moved into the role of Director of process chemistry and route design in early 2012 and then to the role of Technology, Design and Development Advisor for the Lilly development organization and then to the Clinical Innovation Group at Lilly. During Ken’s final years at Lilly, he lead a team of scientists to develop and fly five experiments on the International Space Station. In May 2017, Ken retired from Lilly and is currently a Director on Scientific Partnering at the International Space Station US National Lab.